ArticleThe Journal of clinical investigation2016
Selection bias: maintaining less-differentiated T cells for adoptive immunotherapy.
Article in The Journal of clinical investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Biomaterial-Based Therapeutic Delivery of Immune Cells.Advanced healthcare materials · 2025Review
- Functionalized nanowires for miRNA-mediated therapeutic programming of naïve T cells.Nature nanotechnology · 2024Article
- Implantable CAR T cell factories enhance solid tumor treatment.Biomaterials · 2024Article
- CAR-T treatment for cancer: prospects and challenges.Frontiers in oncology · 2023Review
- Article
- Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells.Nature biotechnology · 2022Article
- Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.Journal of genetics and genomics = Yi chuan xue bao · 2020Review
- The Antitumor Effects of Vaccine-Activated CD8Cancer immunology research · 2017Article
- Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs.International journal of nanomedicine · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical application of T cell immunotherapy depends on ex vivo modification and expansion of T cells for adoptive transfer. In preclinical models, the use of a purified, naive T cell subset enhances persistence and antitumor immunity; however, the majority of clinical studies rely on modification of mixed populations of T cells that contain only a small subset of highly functional T cells with less-differentiated phenotype. In this month's issue of the JCI, Klebanoff and colleagues uncover a Fas-mediated interaction between naive T cells and antigen-experienced T cells that drives differentiation and impairs adoptive immunotherapy. Further, they show that blockade of Fas signaling enhances antitumor immunity and increases survival in a mouse model of melanoma. Their work supports a growing body of evidence that the use of naive T cells enhances the efficacy of adoptive T cell therapy and suggests a new therapeutic strategy for preserving less-differentiated T cell populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.